The International Society for Stem Cell Research (ISSCR) has announced a pivotal advancement in the realm of biomedical research with the formation of the ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development. Bayer, a global leader in life sciences, stands prominently as a Founding Member of this groundbreaking consortium. This initiative represents a cross-sectoral, international effort that seeks to accelerate the responsible integration of human stem cell-derived models into the preclinical phases of drug development, marking a transformative step in the evolution of pharmaceutical science.
The consortium is co-chaired by Daniela Cornacchia from AstraZeneca and Shuibing Chen from Weill Cornell Medicine, highlighting the collaborative nucleus of academic excellence and industry expertise fueling this endeavor. Their leadership underscores a coordinated, global approach towards the regulatory qualification and mainstream adoption of human stem cell-derived systems, which include organoids, engineered tissues, and microphysiological systems. Collectively, these models fall under the umbrella of New Approach Methodologies (NAMs)—cutting-edge tools designed to refine and enhance the drug discovery and development pipeline.
The primary mission of the consortium involves the establishment of standardized frameworks for evaluating these advanced stem cell-based models. This includes defining clear performance criteria and developing regulatory guidance aimed at ensuring that these models are fit-for-purpose within drug safety and efficacy assessments. By harmonizing criteria and methodologies across various research and regulatory entities worldwide, the consortium endeavors to foster greater consistency and reliability in preclinical decision-making processes.
A cornerstone of the consortium’s strategy is the creation of a robust infrastructure to aggregate, harmonize, and benchmark extensive multi-site datasets. Such datasets will enable the comparison of model performances against clinical outcomes, advancing the predictive accuracy and translational relevance of stem cell-based NAMs. Furthermore, the consortium aims to establish an interoperable data ecosystem, featuring an open-access repository dedicated to the collective wealth of stem cell-derived NAM data. This platform is envisioned to spur innovation by promoting transparency, reproducibility, and collaborative analysis within the scientific community.
These concerted efforts intend to bolster regulatory confidence in stem cell-derived NAMs, facilitating their validation and eventual integration into standard drug discovery pipelines. This synergy between academia, industry, and regulatory bodies is poised to reduce the reliance on traditional animal models, offering human-relevant alternatives that may improve the predictability of preclinical testing and accelerate therapeutic development timelines.
Recent shifts in regulatory policies globally have shown increasing openness to NAMs, reflecting a paradigm shift towards embracing human-based research models. The consortium’s initiatives align directly with this progressive regulatory landscape, setting the stage for a future where stem cell-based methodologies play a central role in evaluating drug safety and efficacy prior to clinical trials. This is anticipated to not only foster more ethical research practices but also facilitate the development of precision medicines tailored to human biology.
Keith Alm, CEO of ISSCR, emphasizes the transformative potential of this partnership, noting Bayer’s critical role as a founding member. He highlights that decades of rigorous stem cell research have laid a solid scientific foundation for these models. Now, with Bayer’s commitment and the consortium’s collective efforts, there is a clear pathway towards translating this foundational knowledge into tangible tools, standards, and infrastructures essential for the responsible deployment of stem cell-based technologies in drug development.
The consortium also includes other key players such as the Burroughs Wellcome Fund as a Founding Member and Xellar Biosystems as a Contributing Member, underscoring the diverse stakeholders committed to advancing this frontier. This broad base of support is critical in ensuring the consortium’s initiatives are comprehensive, reflect diverse perspectives, and ultimately achieve widespread adoption.
Further engagement with the scientific community is planned, including a featured session titled “ISSCR Consortium: Stem Cell Models for Drug Development” at the ISSCR 2026 Annual Meeting in Montréal, Canada. This session promises to be a pivotal forum for dialogue, providing attendees an in-depth look at the consortium’s goals, evolving priorities, and implementation timeline. Moreover, it will facilitate ongoing collaboration and feedback, essential for refining the approaches and tools developed.
At its core, the ISSCR Consortium on Advanced Stem Cell-Based Models represents a transformative era for drug discovery and development, seamlessly integrating cutting-edge stem cell science with regulatory science and data management. This collaborative model fosters a future where human-based preclinical testing not only enhances drug safety and efficacy but also streamlines development processes, ultimately benefiting patients through more predictive and personalized therapeutics.
In summary, the ISSCR Consortium stands at the forefront of a paradigm shift in biomedical research. By uniting leading industrial, academic, and regulatory leaders, it pioneers the responsible incorporation of stem cell-derived NAMs into the preclinical landscape. Its mission to standardize evaluation metrics, build interoperable data infrastructures, and promote regulatory acceptance could profoundly reshape drug development. Bayer’s active leadership role signals a commitment to innovation and patient-centric science, paving the way for a new standard of translational research grounded in human biology.
Subject of Research: Advanced stem cell-based models for drug discovery and development
Article Title: ISSCR Consortium Accelerates Integration of Stem Cell-Derived Models in Preclinical Drug Development
News Publication Date: Not explicitly provided in the text
Web References:
– ISSCR Consortium on Advanced Stem Cell-Based Models in Drug Discovery and Development: https://www.isscr.org/stem-cell-models-consortium
– Bayer: https://www.bayer.com/en/
– Burroughs Wellcome Fund: https://www.bwfund.org/
– Xellar Biosystems: https://xellarbio.com/
– ISSCR 2026 Annual Meeting: http://www.isscr2026.org/
References: N/A
Image Credits: N/A
Keywords: Stem cell research, drug discovery, New Approach Methodologies, preclinical drug development, organoids, engineered tissues, microphysiological systems, regulatory qualification, data harmonization, translational research, pharmaceutical innovation, ISSCR consortium
Tags: Bayer in biomedical researchengineered tissue drug testingglobal collaboration in drug developmenthuman stem cell-derived modelsISSCR Consortium on stem cell modelsmicrophysiological systems in medicineNew Approach Methodologies (NAMs)organoids in pharmaceutical sciencepreclinical drug development advancementsregulatory qualification of stem cell modelsstandardized frameworks for drug evaluationstem cell-based drug discovery
